H.C. Wainwright analyst Swayampakula Ramakanth raised the firm’s price target on Janux Therapeutics (JANX) to $70 from $63 and keeps a Buy rating on the shares after the company provided a clinical data update from the ongoing Phase 1 Study evaluating the PSMA-targeting tumor-activated T-cell engager JANX007 to treat metastatic castration-resistant prostate cancer. JANX007 stacks up well against the competition, the analyst tells investors in a research note. The firm increased its probability of launch for JANX007to 26% from 20%. It says treatment with JANX007 exhibited early indications of antitumor activity with confirmed and unconfirmed partial responses in four of eight of evaluable patients for an overall response rate of 50% and stable disease reported in one additional patient.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on JANX:
- Closing Bell Movers: Zscaler down 8% despite earnings beat
- Janux Therapeutics Reports Promising JANX007 Trial Results
- Janux says emerging JANX007 data demonstrates ‘substantial clinical activity’
- Janux Therapeutics initiated with an Outperform at Leerink
- Janux Therapeutics’ Q3 Report: Financials and Progress
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
